H.C. Wainwright Raises United Therapeutics (UTHR) Target to $600

United Therapeutics Corporation (NASDAQ:UTHR) is one of the Top 10 Stocks Warren Buffett Would Buy in 2026.

On February 26, 2026, H.C. Wainwright raised the price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $600 while maintaining a Buy rating. The company has announced that it is developing a soft mist inhaler for treprostinil, slated for a 2027 launch to treat PAH and PH-ILD. In the analyst note, H.C. Wainwright sees this as a strategic move to counter competitors like Yutrepia while evolving the Tyvaso franchise. The management reaffirmed its target of a $4 billion revenue run rate by late 2027, while it awaits the upcoming Phase 3 data for ralinepag and IPF treatments. The firm anticipates upside to this target.

On the same day, RBC Capital analyst Lisa Walter also raised United Therapeutics Corporation’s (NASDAQ:UTHR) target price from $587 to $643 while keeping an Outperform rating on the stock. Similar to H.C. Wainwright, RBC Capital analyst also cited the new announcement for a soft mist inhaler for Treprostinil that could be preferred over DPIs.

Founded in 1996, United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on rare diseases such as pulmonary arterial hypertension. Its co-headquarters are in Maryland and North Carolina.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Buy in 2026 According to Reddit and 13 High-Quality S&P 500 Financial Stocks According to Hedge Funds.

Disclosure. None. Follow Insider Monkey on Google News.